Picture of Helix Biopharma logo

HBP Helix Biopharma Cashflow Statement

0.000.00%
ca flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapMomentum Trap

Annual cashflow statement for Helix Biopharma, fiscal year end - July 31st, CAD millions except per share, conversion factor applied.

2019
July 31st
2020
July 31st
2021
July 31st
2022
July 31st
2023
July 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSARS
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-7.53-8.56-8.04-6.56-6.29
Depreciation
Non-Cash Items0.397-0.365-1.410.9350.564
Discontinued Operations
Unusual Items
Other Non-Cash Items
Changes in Working Capital1.47-2.11-0.054-0.8930.186
Change in Accounts Receivable
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities-5.53-10.8-9.3-6.51-5.53
Capital Expenditures-0.004-0.0160-0.01
Purchase of Fixed Assets
Other Investing Cash Flow Items1.722.0200.005
Sale of Business
Sale of Fixed Assets
Other Investing Cash Flow
Cash from Investing Activities-0.0041.72.020-0.005
Financing Cash Flow Items1.0600.999
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities5.4113.16.566.213.09
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-0.164.03-0.67-0.313-2.44